| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
miR-3175, miR-2278 |
| Biological function: |
hsa_circ_0058493 may serve as a biomarker for diagnosing silicosis and IPF; its knockdown inhibits fibrotic molecule expression in vitro and may affect epithelial-mesenchymal transition. |
| Molecular mechanism: |
hsa_circ_0058493 knockdown inhibited fibrotic molecule expression by affecting the epithelial-mesenchymal transition process; it was predicted to act as a sponge for miR-3175 and miR-2278, potentially modulating downstream signaling pathways and target genes. |
| Biological pathway or process: |
fibrosis (promotes); EMT (promotes); ceRNA regulation (other); PI3K/AKT (promotes) |
| Detected method: |
Q
S
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RT-qPCR; RNA-seq; Microarray; Clinical Sample Validation; Transfection; Western Blot; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
hsa_circ_0058493 could potentially serve as a novel biomarker for silicosis and IPF diagnosis; AUC was 0.845 for silicosis and 0.823 for IPF. |
| Description: |
hsa_circ_0058493 is up-regulated in peripheral blood-related samples from silicosis and IPF patients and shows diagnostic biomarker potential for both diseases. In TGF-beta1-treated MRC-5 lung fibroblasts, its expression increases, while siRNA-mediated knockdown reduces fibrotic molecule expression and affects EMT-related markers. The paper further predicts that hsa_circ_0058493 may function through a ceRNA-like mechanism involving miR-3175/miR-2278 and downstream fibrosis-related pathways, although this mechanism was not experimentally confirmed. |
| Confidence score: |
0.7586 |